Myriad Genetics, Inc. (MYGN)
4.35
+0.20
(+4.82%)
USD |
NASDAQ |
Oct 15, 16:00
4.345
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Cash from Operations (TTM) : 7.70M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.70M |
| March 31, 2026 | 2.40M |
| December 31, 2025 | 1.80M |
| September 30, 2025 | -2.20M |
| June 30, 2025 | -22.60M |
| March 31, 2025 | -6.40M |
| December 31, 2024 | -8.70M |
| September 30, 2024 | -70.00M |
| June 30, 2024 | -92.80M |
| March 31, 2024 | -96.30M |
| December 31, 2023 | -110.90M |
| September 30, 2023 | -63.90M |
| June 30, 2023 | -44.30M |
| March 31, 2023 | -93.70M |
| December 31, 2022 | -107.00M |
| September 30, 2022 | -109.20M |
| June 30, 2022 | -146.00M |
| March 31, 2022 | -100.10M |
| December 31, 2021 | 17.00M |
| September 30, 2021 | 55.90M |
| June 30, 2021 | 112.00M |
| March 31, 2021 | 114.50M |
| June 30, 2020 | 59.70M |
| March 31, 2020 | 62.20M |
| December 31, 2019 | 52.00M |
| Date | Value |
|---|---|
| September 30, 2019 | 91.70M |
| June 30, 2019 | 83.70M |
| March 31, 2019 | 100.10M |
| December 31, 2018 | 105.00M |
| September 30, 2018 | 100.20M |
| June 30, 2018 | 115.90M |
| March 31, 2018 | 104.60M |
| December 31, 2017 | 134.20M |
| September 30, 2017 | 132.60M |
| June 30, 2017 | 106.20M |
| March 31, 2017 | 108.10M |
| December 31, 2016 | 129.00M |
| September 30, 2016 | 138.50M |
| June 30, 2016 | 166.30M |
| March 31, 2016 | 178.84M |
| December 31, 2015 | 146.72M |
| September 30, 2015 | 158.42M |
| June 30, 2015 | 140.50M |
| March 31, 2015 | 130.39M |
| December 31, 2014 | 111.76M |
| September 30, 2014 | 106.71M |
| June 30, 2014 | 190.21M |
| March 31, 2014 | 212.28M |
| December 31, 2013 | 238.43M |
| September 30, 2013 | 212.99M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Natera, Inc. | 228.24M |
| Sera Prognostics, Inc. | -27.68M |
| BioRestorative Therapies, Inc. | -11.82M |
| CareDx, Inc. | 93.66M |
| Exagen, Inc. | -6.498M |